|
Development of bioconjugates for targeted tumor therapy of cancer types leading to high mortality
|
Help
Print
|
Here you can view and search the projects funded by NKFI since 2004
Back »
|
|
List of publications |
|
|
Sabine Schuster: Synthesis of GnRH and Somatostatin Cytotoxic Drug Conjugates, ELTE Doktori Iskola, 2019 | Andrea Angello Pierluigi Tripodi: Development of a novel class of cyclic NGR peptides for targeted drug delivery, ELTE Doktori Iskola, 2020 | Ivan Randelovic: Small molecule peptide-drug conjugates for targeted drug delivery in cancer therapy, Semmelweis Egyetem Doktori Iskola, 2021 | Pethő Lilla: IRÁNYÍTOTT TUMORTERÁPIÁBAN ALKALMAZHATÓ HATÓANYAG-PEPTID KONJUGÁTUMOK HATÁSÁT BEFOLYÁSOLÓ TÉNYEZŐK VIZSGÁLATA, ELTE Doktori Iskola, 2019 | Pethő L, OLáh-Szabó R, Mező G.: Influence of the Daunomycin Position on Bioactivity in Angiopep-2 - Drug Conjugates, 36th EPS Proceedings, 2022 | Dókus LE, Lajkó E, Szász ZA, Vári-Mező D, Takács A, Kőhidai L, Mező G: Development of Pancreatic Tumor Specific Daunomycin – Peptide Conjugates Using Homing Peptides Selected by Phage Display Technique, 36th EPS Proceedings, 2022 | Baranyai Z, Biri-Kovács B, Krátký M, Szeder B, Debreczeni ML, Budai J, Kovács B, Horváth L, Pári E, Németh Z, Cervenak L, Zsila F, Méhes E, Kiss É, Vinšová J, Bősze S.: Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based in Vitro Platforms, J Med Chem 64: 2982-3005, 2021 | Vári B, Dókus L, Borbély A, Gál A, Vári-Mező D, Randelovic I, Varga Z, Szoboszlai N, Mező G, Tóvári J: SREKA-targeted liposome for targeted therapy of highly metastatic cancers, Drug Delivery (submitted), 2022 | Schuster S, Juhász É, Halmos G, Neundorf I, Gennari C, Mező G.: Development and biochemical characterization of self-immolative linker containing GnRH-III-drug conjugates., Int. J. Mol. Sci. 23, 5071, 2022 | Kiss K, Hegedüs K, Vass P, Vári-Mező D, Farkas A, Nagy ZK, Molnár L, Tóvári J, Mező G, Marosi G.: Development of fast-dissolving dosage forms of curcuminoids by electrospinning for potential tumor therapy application., Int. J. Pharm. 611: 121327, 2022 | Farkasinszky G, Dénes N, Rácz Sz, Kis A, Péliné Szabó J, Opposits G, Veres G, Balkay L, Kertész I, Mező G, Hunyadi J, Trencsényi Gy.: In vivo imaging of ischemia/reperfusion-mediated Aminopeptidase N expression in surgical rat model using 68Ga-NOTA-c(NGR)., IN VIVO 36: 657-666, 2022 | Szabo JP, Denes N, Arato V, Racz S, Kis A, Opposits G, Kepes Z, Hajdu I, Joszai I, Emri M, Kertesz I, Mezo G, Trencsenyi G.: In Vivo Imaging of Neo-angiogenesis of Transplanted Metastases in Subrenal Capsule Assay Induced Rat Model, In Vivo 36: 1667-1675, 2022 | Enyedi KN, Tóth S, Szakács G, Mező G: NGR-peptide-drug conjugates with dual targeting properties, PLOS ONE 12: (6) e0178632, 2017 | Schuster S, Biri-Kovács B, Szeder B, Farkas V, Buday L, Szabó Z, Halmos G, Mező G.: Synthesis and in vitro biochemical evaluation of oxime bondlinked daunorubicin–GnRH-III conjugates developed for targeted drug delivery, Beilstein J Org Chem 14: 756-771, 2018 | Tripodi AAP, Tóth S, Enyedi KN, Schlosser G, Szakács G, Mező G.: Development of novel cyclic NGR peptide–daunomycin conjugates with dual targeting property, Beilstein J Org Chem 14: 911-918, 2018 | Vrettos EI, Mező G, Tzakos A.: On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site, Beilstein J Org Chem 14: 930-954, 2018 | Polgár L, Lajkó E, Soós P, Láng O, Manea M, Merkely B, Mező G, Kőhidai L.: Drug targeting to decrease cardiotoxicity – determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human, Beilstein J Org Chem 14: 1583-1594, 2018 | Schuster S, Biri-Kovács B, Borbély A, Sewald N, Neundorf I, Gennari C, Mező G.: Synthesis and biochemical evaluation of GnRH-III-drug conjugates, J. Pept. Sci. SI. p. 79, 2018 | Tripodi AAP, Tóth S, Randelovic I, Tóvári J, Mező G.: NGR-Dau conjugates a favorable tumor-homing motif with potential dual-targeting, J. Pept. Sci. SI. p. 162, 2018 | Enyedi KN, Tripodi AAP, Mező G.: Biochemical-activity studies of NGR-peptide-drug conjugates for targeted tumour therapy, J. Pept. Sci. SI. p. 166-167, 2018 | Pethő L, Murányi J, Kram N, Bökönyi G, Csík G, Mező G.: Synthesis and in vitro biological effect of GnRH-porphyrin IX conjugate, J. Pept. Sci. SI. p. 167, 2018 | Adorján AE, Bősze S, Szabó I, Mező G.: Structure-activity relationship of HER2 receptor targeting peptide and its derivatives in targeted tumor therapy, J. Pept. Sci. SI. p. 167-168, 2018 | Lajkó E, Spring S, Hegedüs R, Biri-Kovács B, Ingebrandt S, Mező G, Kőhidai L.: Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty ac, Beilstein J Org Chem 14: 2495-2509, 2018 | Schuster S, Biri-Kovács B, Szeder B, Farkas V, Buday L, Szabó Z, Halmos G, Mező G.: Synthesis and in vitro biochemical evaluation of oxime bondlinked daunorubicin–GnRH-III conjugates developed for targeted drug delivery, Beilstein J Org Chem 14: 756-771, 2018 | Tripodi AAP, Tóth S, Enyedi KN, Schlosser G, Szakács G, Mező G.: Development of novel cyclic NGR peptide–daunomycin conjugates with dual targeting property, Beilstein J Org Chem 14: 911-918, 2018 | Vrettos EI, Mező G, Tzakos A.: On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site, Beilstein J Org Chem 14: 930-954, 2018 | Polgár L, Lajkó E, Soós P, Láng O, Manea M, Merkely B, Mező G, Kőhidai L.: Drug targeting to decrease cardiotoxicity – determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human, Beilstein J Org Chem 14: 1583-1594, 2018 | Schuster S, Biri-Kovács B, Borbély A, Sewald N, Neundorf I, Gennari C, Mező G.: Synthesis and biochemical evaluation of GnRH-III-drug conjugates, Proceedings of the 35th European Peptide Symposium, pp. 80-83, 2018 | Tripodi AAP, Tóth S, Randelovic I, Tóvári J, Mező G.: NGR-Dau conjugates a favorable tumor-homing motif with potential dual-targeting, Proceedings of the 35th European Peptide Symposium, pp. 297-299, 2018 | Enyedi KN, Tripodi AAP, Mező G.: Biochemical-activity studies of NGR-peptide-drug conjugates for targeted tumour therapy, Proceedings of the 35th European Peptide Symposium, pp. 315-316, 2018 | Pethő L, Murányi J, Kram N, Bökönyi G, Csík G, Mező G.: Synthesis and in vitro biological effect of GnRH-porphyrin IX conjugate, Proceedings of the 35th European Peptide Symposium, pp. 317-319, 2018 | Adorján AE, Bősze S, Szabó I, Mező G.: Structure-activity relationship of HER2 receptor targeting peptide and its derivatives in targeted tumor therapy, Proceedings of the 35th European Peptide Symposium, pp. 320-322, 2018 | Lajkó E, Spring S, Hegedüs R, Biri-Kovács B, Ingebrandt S, Mező G, Kőhidai L.: Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty ac, Beilstein J Org Chem 14: 2495-2509, 2018 | Kiss K, Biri-Kovács B, Szabó R, Ranđelović I, Enyedi KN, Schlosser G, Orosz Á, Kapuvári B, Tóvári J, Mező G.: Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems, Eur J Med Chem. 176:105-116., 2019 | Pethő L, Mező G, Schlosser G.: Overcharging Effect in Electrospray Ionization Mass Spectra of Daunomycin-Tuftsin Bioconjugates., Molecules. 16;24(16), 2019 | Lajkó E, Hegedüs R, Mező G, Kőhidai L.: Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells., Int J Mol Sci. 20: 4421, 2019 | Schuster S, Biri-Kovács B, Szeder B, Buday L, Gardi J, Szabó Z, Halmos G, Mező G.: Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification., Pharmaceutics. 10(4):223., 2018 | Randelovic I, Schuster S, Kapuvári B, Fossati G, Steinkühler C, Mező G, Tóvári J.: Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice, Int J Mol Sci. 20: 4763, 2019 | Pethő L, Murányi J, Pénzes K, Gurbi B, Brauswetter D, Halmos G, Csík G, Mező G:: Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers., Int J Mol Sci, 20: 5027, 2019 | Tripodi AAP, Randelovic I, Biri-Kovács B, Szeder B, Mező G, Tóvári J.: In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunomycin conjugates developed for targeted drug delivery, Pathology & Oncology Research, 2019 | Tripodi AAP, Randelovic I, Biri-Kovács B, Szeder B, Mező G, Tóvári J.: In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunomycin conjugates developed for targeted drug delivery, Pathology & Oncology Research, 26(3): 1879-1892, 2020 | Biri-Kovács B, Adorján A, Szabó I, Szeder B, Bősze S, Mező G.: Structure-activity relationship of HER2 receptor targeting peptide and its derivatives in targeted tumor therapy., Biomolecules 10(2): pii: E183., 2020 | Pethő, L, Kasza G, Lajkó E, Láng O, Kőhidai L, Iván B, Mező G.: Amphiphilic drug-peptide-polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of th, Soft Matter 16: 5759-5769, 2020 | Kiss K, Vass P, Farkas A, Hirsch E, Szabó E, Mező G, Nagy ZK, Marosi G.: A solid doxycycline HP-β-CD formulation for reconstitution (iv bolus) prepared by scaled-up electrospinning., Int J Pharm. 586: 119539, 2020 | Dókus LE, Lajkó E, Randelovic I, Mező D, Schlosser G, Kőhidai L, Tóvári J, Mező G.: Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer., Pharmaceutics 12: 576, 2020 | Al-Majidi M, Szabó D, Dókus L, Steckel A, Mező G, Schlosser G.: Energy‐resolved HCD fragmentation of daunorubicin‐peptide conjugates, J Mass Spectrom 55(10): e4641., 2020 | Kis A, Dénes N, Szabó JP, Arató V, Jószai I, Enyedi KN, Lakatos Sz, Garai I, Mező G, Kertész I, Trencsényi Gy.: In vivo assessment of aminopeptidase N (APN/CD13) specificity of different 68Ga-labelled NGR derivatives using PET/MRI imaging., Int J Pharm. 589: 119881, 2020 | Tripodi AAP, Randelovic I, Biri-Kovács B, Szeder B, Mező G, Tóvári J.: In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunomycin conjugates developed for targeted drug delivery, Pathology & Oncology Research, 26(3): 1879-1892, 2020 | Biri-Kovács B, Adorján A, Szabó I, Szeder B, Bősze S, Mező G.: Structure-activity relationship of HER2 receptor targeting peptide and its derivatives in targeted tumor therapy., Biomolecules 10(2): pii: E183., 2020 | Pethő, L, Kasza G, Lajkó E, Láng O, Kőhidai L, Iván B, Mező G.: Amphiphilic drug-peptide-polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of th, Soft Matter 16: 5759-5769, 2020 | Kiss K, Vass P, Farkas A, Hirsch E, Szabó E, Mező G, Nagy ZK, Marosi G.: A solid doxycycline HP-β-CD formulation for reconstitution (iv bolus) prepared by scaled-up electrospinning., Int J Pharm. 586: 119539, 2020 | Dókus LE, Lajkó E, Randelovic I, Mező D, Schlosser G, Kőhidai L, Tóvári J, Mező G.: Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer., Pharmaceutics 12: 576, 2020 | Al-Majidi M, Szabó D, Dókus L, Steckel A, Mező G, Schlosser G.: Energy‐resolved HCD fragmentation of daunorubicin‐peptide conjugates, J Mass Spectrom 55(10): e4641., 2020 | Kis A, Dénes N, Szabó JP, Arató V, Jószai I, Enyedi KN, Lakatos Sz, Garai I, Mező G, Kertész I, Trencsényi Gy.: In vivo assessment of aminopeptidase N (APN/CD13) specificity of different 68Ga-labelled NGR derivatives using PET/MRI imaging., Int J Pharm. 589: 119881, 2020 | Borbély A, Pethő L, Szabó I, Al-Majidi M, Steckel A, Nagy T, Kéki S, Kalló G, Csősz É, Mező G, Schlosser G.: Structural characterization of daunomycin-peptide conjugates by various tandem mass spectrometric techniques., Int J Mol Sci 22: 1648, 2021 | Dénes N, Kis A, Szabó JP, Jószai I, Hajdu I, Arató V, Enyedi KN, Mező G, Hunyadi J, Trencsényi G, Kertész I.: In vivo preclinical assessment of novel 68Ga-labelled peptides for imaging of tumor associated angiogenesis using positron emission tomography imaging., APPLIED RADIATION AND ISOTOPES 174: 109778, 2021 | Kis A, Dénes N, Szabó JP, Arató V, Beke L, Matolay O, Enyedi KN, Méhes G, Mező G, Bai P, Kertész I, Trencsényi G.: In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68 Ga-NODAGA-c(NGR) Peptide, Biomed Res Int 2021: Article No.: 6642973, 2021 | Dókus Levente E., Lajkó Eszter, Ranđelović Ivan, Mező Diána, Schlosser Gitta, Kőhidai László, Tóvári József, Mező Gábor: Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer, PHARMACEUTICS 12: (6) p. 576., 2020 | Kiss Krisztina, Vass Panna, Farkas Attila, Hirsch Edit, Szabó Edina, Mező Gábor, Nagy Zsombor K., Marosi György: A solid doxycycline HP-beta-CD formulation for reconstitution (i.v. bolus) prepared by scaled-up electrospinning, INTERNATIONAL JOURNAL OF PHARMACEUTICS 586: 119539, 2020 | Pethő Lilla, Kasza György, Lajkó Eszter, Láng Orsolya, Kőhidai László, Iván Béla, Mező Gábor: Amphiphilic drug–peptide–polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of conjugate aggregation on in vitro activity, SOFT MATTER 16: (24) pp. 5759-5769., 2020 | Pethő Lilla, Kasza György, Lajkó Eszter, Láng Orsolya, Kőhidai László, Iván Béla, Mező Gábor: Amphiphilic drug–peptide–polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of conjugate aggregation on in vitro activity, SOFT MATTER 16: (24) pp. 5759-5769., 2020 | Tripodi A.A.P., Ranđelović I., Biri-Kovács B., Szeder B., Mező G., Tóvári J.: In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery, PATHOLOGY AND ONCOLOGY RESEARCH 26: (3) pp. 1879-1892., 2020 | Ranđelović Ivan, Schuster Sabine, Kapuvári Bence, Fossati Gianluca, Steinkühler Christian, Mező Gábor, Tóvári József: Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20: (19) p. 4763., 2019 | Sabine Schuster, Beáta Biri-Kovács, Bálint Szeder, Viktor Farkas, László Buday, Zsuzsanna Szabó, Gábor Halmos, Gábor Mező: Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery, BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY 14: pp. 756-771., 2018 | Schuster Sabine, Biri-Kovács Beáta, Szeder Bálint, Buday László, Gardi János, Szabó Zsuzsanna, Halmos Gábor, Mező Gábor: Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification, PHARMACEUTICS 10: (4) 233, 2018 | Vrettos EI, Mező G, Tzakos AG: On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site, BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY 14: pp. 930-954., 2018 | Enyedi KN, Toth S, Szakacs G, Mezo G: NGR-peptide-drug conjugates with dual targeting properties., PLOS ONE 12: (6) e0178632, 2017 |
|
|
|
|
|
|
Back »
|
|
|